CeNeRx BioPharma TriRima shows good safety profile in study
CeNeRx said that these positive results further confirm the good safety profile demonstrated by TriRima in Phase I studies and set the stage for a Phase II clinical
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
OncoMed’s lead candidate, OMP-21M18, is currently in Phase Ib clinical trials. OncoMed’s pipeline also includes several preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed Pharma